<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70574">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998841</url>
  </required_header>
  <id_info>
    <org_study_id>GN28352</org_study_id>
    <nct_id>NCT01998841</nct_id>
  </id_info>
  <brief_title>A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort.</brief_title>
  <official_title>A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY IN PRECLINICAL PSEN1 E280A MUTATION CARRIERS RANDOMIZED TO CRENEZUMAB OR PLACEBO, AND IN NONRANDOMIZED, PLACEBO-TREATED NONCARRIERS FROM THE SAME KINDRED, TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN THE TREATMENT OF AUTOSOMAL-DOMINANT ALZHEIMER'S DISEASE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>INVIMA: Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This  randomized, double-blind, placebo-controlled, parallel group, adaptive stu dy will
      evaluate the efficacy and safety of crenezumab versus placebo in individ uals who carry the
      PSEN1 E280A autosomal-dominant mutation and do not meet  the criteria for mild cognitive
      impairment due to Alzheimer disease or dementia due to Alzheimer disease and are, thus, in a
      preclinical phase of Alzheimer disease.

      Patients will be randomized 1 : 1 to receive either crenezumab or placebo subcu taneously
      every 2 weeks for 260 weeks. The study also includes a cohort of PSEN1 E280A mutation
      noncarriers who will be dosed with placebo only.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score (including Word List: Recall, Multilingual Naming Test, MMSE, CERAD Constructional Praxis, Raven's Progressive Matrices)</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to mild cognitive impairment (MCI) due to AD or to dementia due to AD</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Dementia Rating (CDR) global score of &gt; 0</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDR Scale-Sum of boxes</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in episodic memory measure: Free and Cued Selective Reminding Task (FCSRT)</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in measure of overall neurocognitive functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean cerebral fibrillar amyloid accumulation</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in regional cerebral metabolic rate of glucose (CMRrI)</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain atrophy measured by volumetric measurements using MRI</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a tau-based cerebral spinal fluid biomarker</measure>
    <time_frame>from baseline to Week 260</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Noncarriers of Mutation: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crenezumab</intervention_name>
    <description>SC every 2 weeks</description>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>SC every 2 weeks</description>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_label>Noncarriers of Mutation: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients,  &gt;/= 30 and &lt;/= 60 years of age

          -  Membership in PSEN1 E280A mutation carrier kindred

          -  Agrees to conditions of, and is willing to undergo, genetic testing (e.g., APOE,
             PSEN1 E280A, and other genetic testing)

          -  PSEN1 E280A mutation carrier or noncarrier status has been confirmed prior to or
             during the screening period

          -  MMSE &gt;/= 26

          -  Does not meet criteria for dementia due to AD (McKhann 2011)

          -  Does not meet criteria for MCI due to AD (Albert 2011)

          -  Adequate vision and hearing in the investigator's judgment to be able to complete
             testing

          -  Women of childbearing potential and men with partners of childbearing potential must
             agree to remain abstinent or use adequate methods of contraception as defined by
             protocol during the treatment period and for at least 16 weeks after the last dose of
             study drug

          -  Study partner who agrees to participate in the study and is capable of and willing to
             accompany the participant to all visits requiring the following:

               -  In-person attendance of the study partner

               -  Information for required telephone assessments

               -  Sufficient time with the participant to be familiar with his/her overall
                  function and behavior

          -  Participant and study partner have evidence of adequate premorbid functioning (e.g.,
             intellectual, visual, and auditory)

          -  Participant and study partner are fluent in, and able to read, the language in which
             study assessments are administered

          -  Willing and able to undergo neuroimaging (PET and MRI)

          -  Serum TSH and B12 within normal or expected range for the testing laboratory If
             participant is taking thyroid hormone, corresponding test values within the normal or
             expected ranges If participant is taking vitamin B12 injection, level at or above the
             lower limit of normal

          -  Taking stable doses of all prescription (not including antidepressants) and
             nonprescription medications (including nutritional supplements) for the treatment of
             non-excluded medical condition(s) for at least 30 days prior to the screening visit.

        Stable doses of antidepressants maintained for 6 weeks prior to the screening visit.

          -  In good general health with no known co-morbidities expected to interfere with
             participation in the study

        Exclusion Criteria:

          -  Significant medical, psychiatric, or neurological condition or disorder documented by
             history, physical, neurological, laboratory, or ECG examination that would place the
             participant at undue risk in the investigator's judgment or impact the interpretation
             of efficacy

          -  History of stroke Participants with a history of transient ischemic attack may be
             enrolled if the event occurred &gt;/= 2 years prior to screening

          -  History of severe, clinically significant (persistent neurological deficit or
             structural brain damage) central nervous system trauma (e.g. cerebral contusion)

          -  Body weight &lt;40 or &gt;120 kg

          -  History or presence of atrial fibrillation that poses a risk for future stroke in the
             investigator's judgment

          -  Current presence of bipolar disorder or other clinically significant major
             psychiatric disorder according to DSM-IV-TR or symptom (e.g., hallucinations,
             agitation, paranoia) that could affect the participant's ability to complete
             evaluations

          -  Geriatric Depression Scale (short form) (15-point scale) score &gt; 9 at screening

          -  History of seizures (excluding febrile seizures of childhood)

          -  Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation,
             or uncontrolled hypertension

          -  Pregnant or nursing women, or women who intend to become pregnant or to nurse infants
             during the conduct of this trial

          -  Clinically significant infection within the last 30 days prior to screening

          -  Positive urine test for drugs of abuse at screening

          -  History of alcohol or substance dependence within the previous two years

          -  Use of any other medications with the potential to significantly affect cognition

          -  Use of typical anti-psychotics, barbiturates, or anti-cholinergic antidepressants
             unless used in low doses for conditions other than depression, such as migraine
             headaches, and approved by the medical monitor

          -  Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics
             unless maintained on a stable dose regimen for at least 6 weeks prior to screening

          -  Use of any FDA/INVIMA-approved medications for treatment of LOAD at
             screening/baseline Cholinesterase inhibitors and/or memantine are prohibited during
             the study except in participants enrolled in the study that develop AD dementia.

        Use of anti-coagulant medication, except aspirin (heparinoids, heparin, warfarin, thrombin
        inhibitors, Factor Xa inhibitors), or known coagulopathy or platelet count &lt;100,000
        cells/ÂµL, within 4 weeks of the screening visit

          -  Treatment with any biologic therapy within five half-lives or 3 months prior to
             screening, whichever is longer, with the exception of routinely recommended
             vaccinations, which are allowed

          -  Use of anti-seizure medication (except in childhood for febrile seizures or if used
             for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate)
             medications

          -  Use of investigational drug, device, or experimental medication within 60 days (or
             five half-lives, whichever is longer) of the screening visit

          -  Previous treatment with crenezumab (MABT5102A) or any other therapeutic that targets
             A beta

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric, human, or humanized antibodies or fusion proteins

          -  Contraindication to MRI scan procedures or clinically significant claustrophobia that
             would contraindicate a brain MRI scan

          -  Contraindication to PET scan procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN28352 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Yarumal</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
